Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Authors

Christoph Wanner
Silvio E Inzucchi
John M. Lachin, George Washington UniversityFollow
David Fitchett
Maximilian von Eynatten
Michaela Mattheus
Odd Erik Johansen
Hans J Woerle
Uli C Broedl
Bernard Zinman

Document Type

Journal Article

Publication Date

7-28-2016

Journal

The New England Journal of Medicine

Volume

375

Issue

4

Inclusive Pages

323-334

DOI

10.1056/NEJMoa1515920

Keywords

Benzhydryl Compounds--therapeutic use; Diabetes Mellitus, Type 2--complications; Diabetic Nephropathies--drug therapy; Glucosides--therapeutic use; Hypoglycemic Agents--therapeutic use

APA Citation

Wanner, C., Inzucchi, S., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O., Woerle, H., Broedl, U., & Zinman, B. (2016). Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. The New England Journal of Medicine, 375 (4). http://dx.doi.org/10.1056/NEJMoa1515920

Peer Reviewed

1